The T-Cell Warriors

March 03, 2015

Portrait of a revolutionary approach to cancer treatment in the Pennsylvania Gazette.

Read more

I’d Rather Be in Philadelphia

Published by Elizabeth Azzato, MD, PhD, and other Pathology Residents, on January 30, 2015

A persistent legend has it that the epitaph on the tombstone of W.C. Fields reads “I’d rather be in Philadelphia.” Here are some questions that many of us had when we first considered enrolling in the Pathology Residency Program at Penn and that you might have as well if you don’t know Philly yet.

Read more

Precision Medicine Initiative

January 23, 2015

Dr. David Roth, Director of the Penn Medicine Precision Medicine Program, explains the complexities and the challenges of precision medicine in an interview with WHYY's The Pulse.

Read more

Nature Communications Study Finds New Biomarker Possibilities for Rare Neuroendocrine Tumors

January 21, 2015

A new study published in Nature Communications finds that a mutation in the ATRX gene, a potential molecular marker for aggressive brain tumors, can also serve as a much-needed biomarker for rare neuroendocrine tumors.

Read more

Dr. Nachamkin to Chair ASM Ad Hoc Committee on Assessing Evidence-based Laboratory Medicine Practice Guidelines

December 18, 2014

Assessment of Laboratory Medicine Practice Guidelines is part of a cooperative agreement between the ASM and the CDC to the ensure the development of transparent, rigorous evidence-based guidelines.

Read more

Xu Lab Publishes in Nature Communications

December 16, 2014

New technique to repurpose fibroblasts into functional melanocytes.

Read more

Lambris Lab Demonstrates Way to Tame Inflammatory Response in Kidney Dialysis

December 11, 2014

"Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters" published in Immunobiology. 

Read more

Latest Results of Investigational Cellular Therapy CTL019 at ASH

December 08, 2014

Highlights of the new trial results include a response rate of more than 90 percent among pediatric ALL patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and 45 percent response rate among those with diffuse large B cell lymphoma.

Read more

Dr. Malek Kamoun Elected President of ASHI

November 14, 2014

Dr. Kamoun assumes the 2014-15 Presidency of the American Society for Histocompatibility and Immunogenetics (ASHI).

Read more

Pages